Objective: The objectives of this study were to evaluate the effects of bazedoxifene acetate (BZA), a new selective estrogen receptor modulator, on coronary and peripheral artery atheroscleroses and to determine if it would antagonize the atheroprotective effects of conjugated equine estrogens (CEE) on a monkey model.
P ostmenopausal hormone therapy (PHT) is the only Food and Drug AdministrationY and Health CanadaYapproved therapy for the treatment of menopausal symptoms and the prevention of osteoporosis. Traditional PHT includes estrogen therapy (ET) and, for women with a uterus, estrogen-progestogen therapy (EPT). Over the past decade, the results of a number of studies on both women and nonhuman primates have raised concerns about the potential adverse effects of the progestogen component of EPT. Those concerns are focused primarily on issues about breast cancer risk and the possibility of increased cardiovascular events. The most commonly prescribed estrogenprogestin therapy in the United States has been conjugated equine estrogens (CEE) given with medroxyprogesterone acetate (MPA). 1 In 1996, Cline et al 2 reported the results of a study on surgically postmenopausal cynomolgus monkeys in which CEE + MPA increased breast epithelial proliferation to a greater extent than CEE alone, leading them to conclude that women treated with CEE + MPA may be at greater risk for developing breast neoplasms than women treated with CEE alone. This conclusion was confirmed some years later with data from the Women's Health Initiative randomized clinical trial. 3 CEE therapy, initiated soon after inducing surgical menopause in cynomolgus monkeys, has a robust beneficial effect of inhibiting the initiation and progression of coronary artery atherosclerosis. 4 In one major study using surgically postmenopausal cynomolgus monkeys, MPA was found to antagonize the inhibitory effects of CEE on coronary artery atherosclerosis. 5 More recently, there have been reports on subgroups from the Women's Health Initiative trial all suggesting cardiovascular benefits with CEE, but not with CEE + MPA.
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Taken together, these concerns have resulted in a major research effort to identify a means of protecting the breast and the uterus during postmenopausal ET. The ideal means would be an agent that would act in a tissue-selective manner when combined with ET without increasing the risk for breast and endometrial cancers or adversely affecting the progression of atherosclerosis. It has been suggested that a reasonable approach would be a selective estrogen receptor modulator (SERM) that binds to estrogen receptors > and A with high affinity and acts either as an estrogen agonist or as an estrogen antagonist, depending on the target tissue. 9 Phase 3 clinical trials evaluating the new third-generation SERM, bazedoxifene acetate (BZA), have shown promising results on the treatment of osteoporosis, as well as on the reduction of menopausal symptoms and the prevention of osteoporosis when BZA is used in combination with CEE.
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We have recently completed a randomized, parallel-arm trial with surgically postmenopausal cynomolgus monkeys (Macaca fascicularis) designed to determine the effects of BZA alone, CEE alone, and combined BZA and CEE on the breast, uterus, and cardiovascular system. We have reported that BZA given to monkeys at a clinically relevant dose is an estrogen antagonist capable of abrogating the effects of CEE on the monkey's breast, 14 inhibits estrogen effects on the endometrium, and lacks uterotropic effects when given alone and with CEE. 15 Because CEE given alone to monkeys in the early stage of surgical menopause and to women in the early stage of either surgical or natural menopause effectively reduces the progression of atherosclerosis, we report here the effect of adding BZA to CEE on the extent and severity of coronary and peripheral artery atheroscleroses. Furthermore, because BZA is used for the prevention and treatment of osteoporosis, we report on its lack of adverse effects on the progression of atherosclerosis in a monkey model.
METHODS

Animal participants
One hundred five premenopausal cynomolgus monkeys (M. fascicularis) were obtained through our collaborative association with the Institut Pertanian Bogor (Bogor, Indonesia). The mean estimated age was determined by dentition to be 12 years. During the preexperimental phase, the animals were evaluated for their health status and ovariectomized to induce surgical menopause. After ovariectomy, plasma concentrations of estradiol were monitored to document the completeness of ovariectomy. Five monkeys were excluded because of the presence of ectopic ovarian tissue, one developed diabetes, and one was euthanized for chronic weight loss due to an intestinal disease. All procedures were approved by the Institutional Animal Care and Use Committee of Wake Forest University and conducted in accordance with federal, state, and institutional guidelines. Wake Forest University is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
Study design
The study used a four-group, parallel-arm design, with treatments lasting for 20 months (Fig. 1) . Social groups of monkeys (n = 2-5 per group) were randomly assigned to treatment using a permuted block randomization scheme. This was performed to minimize differences in time when treatments were initiated because groups were started on treatment on a staggered schedule of two social groups every week. Social groups were assigned to one of four experimental groups: no treatment (controls; n = 23), treatment with BZA 20 mg/day (n = 24), treatment with CEE 0.45 mg/day (n = 24), or treatment with BZA 20 mg/day + CEE 0.45 mg/day (n = 27). All doses have been described as women's equivalent doses. To account for the difference in metabolic rate between monkeys and women, we presented the women's dose of CEE (0.45 mg/d) to the monkeys scaled to 1,800 cal of diet (the usual intake of American women). The BZA dose was based on a dose-finding study that determined the amount needed to approximate the blood levels of women administered BZA 20 mg/day, as we have described previously.
14 All monkeys were fed a semipurified diet formulated to be similar to diets consumed by North American women but containing an exaggerated amount of cholesterol necessary to induce sufficient atherosclerotic plaques for evaluation within the time frame of this trial. The diet was prepared at the Wake Forest Primate Center Diet Laboratory, contained cholesterol 0.29 mg/cal, and derived 19% of energy from proteins (casein and lactalbumin), approximately 35% of energy from fats, and approximately 47% of energy from carbohydrates. The monkeys were offered 120 cal of diet per kilogram of body weight daily.
Assessment of cardiovascular risk variables Body weight and adiposity
Body weights were determined at baseline and monthly during the experimental period. The degree of adiposity was assessed at 12 and 20 months after treatment. Our measure of adiposity is generally comparable to body mass index in humans. Trunk length was measured as the distance from the suprasternal notch to the pubic symphysis. The adiposity index was calculated as body weight (kg) divided by trunk length (m 2 ). Duplicate measures of adiposity were made by two technicians, and the mean of the two measurements was recorded.
Plasma lipids/lipoproteins and fasting glucose
After 18-to 24-hour fasting periods, blood samples were collected into EDTA tubes at baseline (4 wk after ovariectomy) and at 3, 6, 12, and 20 months after treatment to determine fasting lipid/lipoprotein and glucose concentrations. Total plasma cholesterol (TPC) concentrations, high-density lipoprotein cholesterol (HDL-C) concentrations, and plasma triglycerides (TG) were determined at the Comparative Medicine Clinical Chemistry and Endocrinology Laboratory using reagents (ACE cholesterol, ACE HDL-C, and ACE TG) and instrumentation (ACE ALERA autoanalyzer) from Alfa Wasserman Diagnostic Technologies (West Caldwell, NJ). TPC and HDL-C were standardized to calibrated controls from the Centers for Disease Control and Prevention, National Heart, Lung, and Blood Lipid Standardization Program. Intra-assay and interassay coefficients of variation were lower than 5% for all analyses. NonYHDL-C, which approximates the sum of low-density lipoprotein cholesterol (LDL-C) and very lowdensity lipoprotein cholesterol, was calculated by subtracting HDL-C from TPC. Plasma glucose concentrations were determined by the glucose oxidase method using Glucose Analyzer 2 (Beckman Instruments, Brea CA).
Necropsy procedures and atherosclerosis evaluations Necropsy procedure
After 20 months of postmenopausal treatment, the monkeys were euthanized with sodium pentobarbital (100 mg/kg, IV), a method consistent with the recommendations of the panel on euthanasia of the American Veterinary Medical Association. The circulatory system was flushed with lactated Ringer's solution, the heart was removed, and the coronary arteries were perfused for 1 hour at a pressure of 100 mm/Hg using 10% neutral buffered formalin.
Coronary arteries
Fifteen blocks (each 3 mm in length) of coronary artery were cut perpendicular to the long axis of the arteries. Five of these were serial blocks from the left circumflex coronary artery (LCX), five were from the left anterior descending coronary artery (LAD), and five were from the right coronary artery (RCA). Each of the 15 blocks was embedded in paraffin, and 5-Km sections were made and stained with Verhoeff-van Gieson's stain. Each section was captured digitally using a Nikon DS Fi1 camera mounted on an Olympus BH-2 microscope equipped with a mechanical stage. Morphometric measurements were made using Image-Pro Plus version 7.0 imaging software (Media Cybernetics Inc., Bethesda, MD). Measurements were performed by a single technician who had more than 20 years of experience and was blinded to treatment and were randomly reevaluated by T.B.C. Plaque extent. Plaque extent is expressed as the cross-sectional area (mm 2 ) of the coronary artery plaque. Plaque extent is expressed as the median plaque areas for each of the three main epicardial coronary arteries (LAD, LCX, and RCA). The details of this approach have been reported previously. 16, 17 Plaque severity. Because plaque complications occur independently of plaque extent, we used a well-established system for assigning severity grade on a scale of 0 to 5. 18 Coronary arteries with normal intima were given a score of 0. Intimal lesions that consisted of smooth muscle adaptive thickening were given a grade of 1. If the smooth muscle adaptive thickening contained macrophage foam cells, a grade of 2 was given. For those cases in which there had been necrosis of macrophages and accumulation of small pools of extracellular lipid, a grade of 3 was recorded. A grade of 4 was recorded for those lesions in which the small pools of extracellular lipid had coalesced into a core of extracellular lipid. The most complicated plaques observed in this study were given a grade of 5 based on the core of extracellular lipid being separated from the lumen by a definitive fibromuscular cap. Plaque severity scores were expressed as the mean maximal severity grade for each of the three main epicardial coronary arteries (LAD, LCX, and RCA). We chose to use the maximal grade because the clinical significance for any one of the coronary arteries relates to its most complicated lesion and not to its average lesion. Grades were determined by three independent observers who were blinded to treatment.
Iliac arteries
The common iliac artery was opened longitudinally, laid flat on cardboard, and immersion-fixed in 10% neutral buffered formalin. The common iliac artery was divided into three congruent blocks cut perpendicular to the long axis of the artery. Blocks were embedded in paraffin, sectioned, stained, and measured as described for the coronary arteries. Plaque extent. Plaque extent (mm 2 ) was determined morphometrically as described for the coronary arteries, and the mean of the three congruent blocks was recorded. Plaque severity. Plaque severity was determined as described for the coronary arteries. The mean maximal grade was recorded. extent (mm 2 ) across the five blocks. Given the highly skewed distribution of plaque size data, nonparametric Kruskal-Wallis test was used to compare treatment group differences, and the extent of atherosclerosis was reported as the median plaque size for each treatment group. Subsequent multiple comparisons relative to the control group were performed using Wilcoxon rank sum tests, and Bonferroni corrections were made accordingly. Atherosclerosis severity was assessed by analyzing the maximal severity score across the five blocks using analysis of variance (ANOVA) to assess treatment effect. Multiple comparisons with the control group were performed using Dunnett's method.
The extent of iliac artery atherosclerosis was computed as the mean plaque area (mm 2 ) across the three blocks for each monkey. Square root transformations were used to achieve better normality and subsequently analyzed using ANOVA. Dunnett's method was used to adjust for multiple comparisons with the control group.
For risk factors such as lipids and glucose, the baseline differences among treatment groups were analyzed using ANOVA. Both baseline and follow-up measures were analyzed together using linear mixed-effects models to assess the pattern of change over time for different treatment groups. Body weight and adiposity index were analyzed with similar ANOVA and mixed-effects models.
RESULTS
Baseline assessment of risk variables
For all variables, except for plasma TG concentrations, there were no significant differences among the groups (Table 1 ).
There were small but statistically significant group differences in TG concentrations among the groups. The small differences were not considered physiologically significant. Table 2 presents the means and standard errors for the risk factors evaluated over the 20-month study. There were no significant group differences in body weight or adiposity (a measure comparable to body mass index in humans). There were no significant differences in plasma lipid profiles among the groups. The plasma TG concentrations tended to be somewhat higher in the BZA and CEE groups, but the differences did not reach statistical significance (P = 0.068). Fasting plasma glucose concentrations were the same for all groups.
Experimental assessment of risk variables
Extent of coronary artery atherosclerosis
The extent of coronary artery atherosclerosis for each monkey was calculated as the mean cross-sectional area of plaques in five congruent sections of the three main epicardial coronary arteries (LAD, LCX, and RCA). Because the data were not distributed normally, the data presented in Figure 2 are the median plaque sizes of each of the three main coronary arteries in the control and treatment groups. Neither BZA alone nor BZA + CEE had any effect on plaque sizes (extent) compared with the control group. A highly significant reduction in the size of coronary artery plaques was observed in all three main coronary arteries in the CEE-treated monkeys.
Severity of coronary artery atherosclerosis
The severity of coronary artery atherosclerosis for each monkey was determined using the well-established grading BZA, bazedoxifene acetate; CEE, conjugated equine estrogens; BW, body weight; TPC, total plasma cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; VLDL + LDL-C, very low-density lipoprotein cholesterol + low-density lipoprotein cholesterol; TPC:HDL-C, ratio of TPC to HDL-C; VLDL + LDL-C:HDL-C, ratio of VLDL + LDL-C to HDL-C. BZA, bazedoxifene acetate; CEE, conjugated equine estrogens; BW, body weight; adiposity, BW / distance from the suprasternal notch to the symphysis pubis; TPC, total plasma cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; VLDL + LDL-C, very low-density lipoprotein cholesterol + lowdensity lipoprotein cholesterol; TPC:HDL-C, ratio of TPC to HDL-C; VLDL + LDL-C:HDL-C, ratio of VLDL + LDL-C to HDL-C. system of the American Heart Association. For each monkey, a grade was given for each of the five congruent sections of the three main epicardial coronary arteries (LAD, LCX, and RCA). Because the clinical significance of plaque severity for an individual coronary artery relates to the maximal grade for that artery, the data presented in Figure 3 are the mean maximal grades for each of the three coronary arteries. Neither BZA administered alone nor BZA + CEE affected the severity of atherosclerotic plaques. Treatment with CEE alone significantly reduced plaque severity.
Extent of common iliac artery atherosclerosis
The extent of common iliac artery atherosclerosis for each monkey was calculated as the mean cross-sectional area of plaques in three congruent sections of the artery. The data presented in Figure 4 are the mean plaque sizes for the control and treatment groups. Much like the coronary arteries, neither BZA alone nor BZA + CEE had any effect on plaque sizes (extent) compared with the control group. Treatment with CEE significantly reduced plaque size compared with the control group.
Severity of common iliac artery atherosclerosis
For each monkey, a grade was given for each of the three congruent sections of the common iliac artery. Because the clinical significance of plaque severity for an individual coronary artery relates to the maximal grade for that artery, the data presented in Figure 5 are the mean maximal grades for   FIG. 2 . Median plaque size for each of the epicardial coronary arteries (presented owing to the skewed distribution of plaque size measures). Probability estimates are nonparametric P values comparing each treatment group to the control group. LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; CTL, control; CEE, conjugated equine estrogens; BZA, bazedoxifene acetate.
FIG. 3.
Mean maximal severity grades by group. Variability is expressed as SEM. Probability estimates are P values comparing each treatment group to the control group using Dunnett's method. LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; CTL, control; CEE, conjugated equine estrogens; BZA, bazedoxifene acetate.
FIG. 4.
Mean common iliac artery plaque sizes (cross-sectional areas of intima) by group. Variability is expressed as SEM. Probability estimates are P values comparing each treatment group to the control group using Dunnett's method. CTL, control; CEE, conjugated equine estrogens; BZA, bazedoxifene acetate. the common iliac artery. Treatment with either BZA or BZA + CEE had no effect on plaque severity. Treatment with CEE significantly reduced plaque severity compared with the control group.
DISCUSSION
Although PHT is generally accepted as the most effective means for the treatment of menopausal symptoms and the prevention of osteoporosis, few issues have been more controversial than the cardiovascular implications of estrogens given alone (ET) or combined with progestin (EPT). The primary purpose of the study reported here was to investigate the cardiovascular effects of a tissue-selective SERM (BZA), given alone or in combination with CEE, on surgically postmenopausal cynomolgus monkeys.
BZA, administered alone or in combination with CEE, had no effect on the body weight or adiposity of the monkeys. The lack of effect on body weight could be considered an important advantage of the combination compared with CEE + MPA because CEE + MPA result in significant increases in the body weight of the monkey model compared with controls or those treated with CEE alone. 19 Long-term studies of the effects of BZA or BZA + CEE on the body weight or body mass index of women have not been reported.
The lack of effect of BZA and BZA + CEE on the plasma lipid profiles of the monkeys is in contrast to the reported effects of these two treatments on the plasma lipid profiles of women. Christiansen et al 20 found that BZA given to postmenopausal women at a dose of 20 mg/day resulted in a median percentage reduction in TPC concentrations of 3.8, a median percentage reduction in LDL-C of 5.4, and an increase in HDL-C of 5.1. That we did not observe a significant effect of CEE treatment on the plasma lipid profiles of the monkeys is consistent with most of our prior studies using the cynomolgus monkey model. 16, 21, 22 In most of our prior studies with CEE, we modeled women's dose of 0.625 mg/day. In the study reported here, we modeled women's CEE dose of 0.45 mg/day. However, we have reported previously that lower doses of CEE administered to the monkey model are as atheroprotective as women's equivalent of 0.625 mg/day. 23 Although we found no effect on the lipid profiles of the monkeys given BZA + CEE, Lobo et al 13 reported rather robust beneficial effects of BZA + CEE on postmenopausal women at the dose of the combination that we modeled in the monkeys (BZA 20 mg/d + CEE 0.45 mg/d). They reported decreases of about 10% in plasma concentrations of LDL-C and increases of about 11% in HDL-C. The differences in the effects of the treatments on the plasma lipid profiles of our monkey model in this trial probably relate to the exaggerated amount of dietary cholesterol used to induce sufficient atherosclerosis for evaluation within the time frame of the trial.
We found no evidence that BZA treatment had any adverse effects on either the extent or the severity of coronary and common iliac artery atheroscleroses. This finding is consistent with an earlier study evaluating raloxifene, a second-generation SERM, in cynomolgus macaques. 24 Despite the lack of beneficial effect of CEE treatment on the plasma lipid profiles of the monkeys, there was robust inhibition of atherosclerosis progression (extent) and plaque severity/complications in all three main epicardial coronary arteries and in the common iliac artery. This finding is comparable to a number of studies we have reported previously, which found that estrogen treatment initiated immediately after inducing surgical menopause in monkeys inhibits the progression of coronary artery atherosclerosis by an average of 70%.
21,25<27 Interestingly, a similar estimate was made for the beneficial effects of estrogen treatment on the progression of carotid artery intimal media thickness in postmenopausal women. 28 The robust atherosclerosis inhibitory effect of CEE on the monkey model is lost with increasing time since menopause, an observation that leads to the so-called Btiming hypothesis.[ 29, 30 Our observation was that the 2-year delay of estrogen treatment (comparable to 6 y in women) after surgical menopauseVa period that allowed the plaques to progress to a complicated stageVresulted in no beneficial effect of the estrogen treatment. 4 We have interpreted this finding as probably being related to the loss of estrogen receptors with advancing atherosclerosis, as described by Losordo et al 31 for humans with advancing atherosclerosis.
Analysis of a large number of monkey studies in which ET was initiated soon after surgical menopause led us to conclude that only about 25% of the atheroprotective effects of estrogens relate to their plasma lipid effects and that about 75% of the beneficial effects are plasma lipidYindependent and presumably direct effects on arteries via estrogen receptors. 32 Our finding that BZA attenuated the beneficial atheroprotective effects of CEE was unexpected and probably relates to the fact that the CEE beneficial effects on the monkeys are primarily receptor-mediated. Much in the same way that BZA protects the breast and the uterus during CEE treatment in the monkey model, it seems to interfere with the estrogen agonist effect on the coronary and iliac arteries.
Some aspects of the translational significance of the monkey study reported here seem clear, but some are unclear. It is clear that BZA had no adverse effects on the progression or severity of coronary and peripheral artery atheroscleroses. It is FIG. 5 . Mean maximal severity grades of common iliac artery plaques by group. Variability is expressed as SEM. Probability estimates are P values comparing each treatment group to the control group using Dunnett's method. CTL, control; CEE, conjugated equine estrogens; BZA, bazedoxifene acetate.
unclear whether some beneficial effects of BZA might have been observed had BZA displayed the same effect on the monkeys' plasma lipid profiles, as has been observed for women. It is clear that the robust atheroprotective effects of CEE administered soon after inducing menopause have again been replicated. In this monkey trial, the addition of BZA to CEE treatment completely attenuated the atheroprotective effects of CEE. It is unclear whether this outcome would have been different had the reductions in LDL-C and the increases in HDL-C reported to occur in women been the case with the monkeys. However, it seems doubtful to us that the outcome would have been different because the protective effects of CEE occur primarily through its direct effects on the artery wall and not through changes in plasma lipids and lipoproteins.
CONCLUSIONS
In this preclinical, nonhuman primate trial, treatment with BZA alone, CEE alone, and combined BZA and CEE does not have significant effects on plasma lipid profiles. CEE treatment markedly inhibits the progression and complications of both coronary and iliac artery atheroscleroses. BZA treatment has no adverse effects on atherosclerosis but attenuates the atheroprotective effects of CEE on both coronary and iliac arteries. Similar to breast and uterine effects, BZA also seems to block the effects of CEE on the artery wall. The translational implications for postmenopausal women seem clear. When BZA alone is used to prevent or treat osteoporosis, there is no indication that atherosclerosis progression will be exacerbated. When CEE is administered in combination with BZA for the treatment of osteoporosis or menopausal symptoms, the potential cardiovascular benefits of CEE may be diminished.
